Skip to main content

Axxam Opts for Spotfire DecisionSite

NEW YORK, June 30 - Milan-based biotech firm Axxam has licensed Spotfire's DecisionSite software, Spotfire said today.

 

Axxam is using an application based on Spotfire's DecisionSite for Lead Discovery software to analyze data produced by Molecular Devices' FLIPR (Fluorometric Imaging Plate Reader) system, Spotfire said.

 

Axxam is also using DecisionSite for Functional Genomics to discover and validate new genomic targets.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.